On the heels of January’s FDA approval of the Senza II Spinal Cord Stimulation (SCS) System (Nevro) to treat back and leg pain, several potential pain indications were presented at the 2018 annual meeting of the North American Neuromodulation Society (NANS), including chronic, intractable neck and/or upper limb pain; peripheral polyneuropathy; and nonsurgical refractory back pain.